Uveal melanoma
Drug research and approvals for uveal melanoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 42 studies of uveal melanoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, FDA has 2 approved and 10 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 42
- Trials authorized in Canada: 10
- FDA orphan approvals: 2
- EU medicines: 1
- High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal…NCT07913412 · Not reported · University Hospital, Essen · starts Sep 1, 2019
- Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug…NCT07863024 · Phase 1 / Phase 2 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaNCT07804186 · Phase 3 · IDEAYA Biosciences · starts Sep 4, 2026
- A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid TumorsNCT07636785 · Phase 1 / Phase 2 · VM Discovery, Inc. · starts Jul 16, 2026
- Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced MelanomaNCT07627698 · Phase 1 / Phase 2 · Beijing Biotech · starts Mar 2, 2026
- Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaNCT07501117 · Phase 1 · Inge Marie Svane · starts Jun 29, 2026
- HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma(FASTIL-Mela02)NCT07406724 · Phase 2 · Hangzhou Huasai Biomedicine Co., Ltd. · starts Feb 26, 2026
- Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverNCT07364474 · Not applicable · Massachusetts General Hospital · starts Jan 27, 2026
- Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaNCT07276386 · Phase 2 · H. Lee Moffitt Cancer Center and Research Institute · starts Dec 31, 2025
Phase 3 9
- Tyrosinase
- GP-100 antigen
- DacarbazineDNA inhibitor
- TebentafuspMelanocyte protein PMEL binding agent
- RanibizumabVascular endothelial growth factor A inhibitor
- SelumetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- MelatoninMelatonin receptor agonist
- FotemustineDNA cross-linking agent
Phase 2 12 of 49
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- Incomplete freund's adjuvant
- PembrolizumabProgrammed cell death protein 1 inhibitor
- TemozolomideDNA inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- TrametinibDual specificity mitogen-activated protein kinase kinase 2 inhibitor
- CarboplatinDNA inhibitor
- PaclitaxelTubulin inhibitor
- AldesleukinInterleukin-2 receptor agonist
- Peginterferon alfa-2bInterferon alpha/beta receptor agonist
- SorafenibSerine/threonine-protein kinase RAF inhibitor
Phase 1 or earlier 12 of 14
- SotrastaurinProtein kinase C (PKC) inhibitor
- IbuprofenCyclooxygenase inhibitor
- TramadolMu opioid receptor agonist
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- PemetrexedThymidylate synthase inhibitor
- AlpelisibPI3-kinase p110-alpha subunit inhibitor
- AvelumabProgrammed cell death 1 ligand 1 other
- EntrectinibNeurotrophic tyrosine kinase receptor inhibitor
- PegargiminaseL-arginine hydrolytic enzyme
- CDX-1140Tumor necrosis factor receptor superfamily member 5 agonist
- SiremadlinTumour suppressor p53/oncoprotein Mdm2 inhibitor
- PAC-1
| Jul 13, 2026 | A randomized, phase 3, open-label study of adjuvant darovasertib and crizotinib in participants with primary non-metastatic uveal melanoma (optimum-11)Darovasertib / Crizotinib | Ideaya Biosciences | Pending |
| Aug 28, 2025 | A randomized, phase 3, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (optimum-10)Darovasertib (IDE196) | Ideaya Biosciences | Ongoing |
| Jan 23, 2025 | A randomized clinical trial evaluating intravitreal faricimab (6.0 mg) injections of fluocinolone acetonide (0.19 mg) intravitreal implants vs. observation for…Faricimab / Fluocinolone | Jaeb Center for Health Research Foundation, Inc | Pending |
| Oct 6, 2023 | Ide196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal…Darovasertib (IDE196) / Crizotinib | Ideaya Biosciences | Ongoing |
| Aug 30, 2023 | (NEO)adjuvant IDE196 (darovasertib) in patients with localized ocular melanomaDarovasertib (IDE196) / Metformin / Norethindrone-ethinyl estradiol | Ideaya Biosciences | Ongoing |
| Aug 12, 2021 | A phase 1/2 study of IDE196 in patients with solid tumors harboring gnaq/11 mutations or prkc fusionsDarovasertib (IDE196)/ Crizotinib | Ideaya Biosciences | Ongoing |
| Jul 14, 2017 | A phase I/II, open-label, multi-center study of the safety and efficacy of IMCGP100 using the intra-patient escalation dosing regimen patients with advanced…IMCGP100 | Immunocore | Ongoing |
| Mar 30, 2017 | A phase II randomized, open-label, multi-center study of the safety and efficacy of IMCGP100 compared with investigator's choice in hla-a*0201 positive…IMCGP100 | Immunocore | Ongoing |
| Apr 9, 2014 | A phase Ib/II, open-label, multicenter study of AEB071 and MEK162 in adult patients with metastatic uveal melanomaMEK162/ AEB071/medronic acid/technetium tc 99M | Novartis Pharmaceuticals | Pending |
| Jan 16, 2014 | A randomised, double-blind study to assess the efficacy of selumetinib (AZD6244, hyd-sulfate) in combination with dacarbazine compared with placebo in…Selumetinib | AstraZeneca Pharmaceuticals | Closed |
| Aug 14, 2023 | HepzatoAs a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the… | Delcath Systems, Inc. | Approved |
| Jan 25, 2022 | KimmtrakTreatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma | Immunocore Ltd | Approved |
| Nov 19, 2025 | Selective histone deacetylase 8 (HDAC8) inhibitorTreatment of uveal melanoma | Novelwise Pharmaceuticals Corporation | Designated |
| Nov 1, 2025 | Anzutresgene autoleucelTreatment of uveal melanoma | Immatics | Designated |
| Sep 17, 2024 | Aptamer-drug conjugate (ApDC) comprising a c-Met aptamer…Treatment of uveal melanoma | Hangzhou Institute of Medicine, Chinese Academy of Sciences | Designated |
| Nov 1, 2022 | [6-Fluoro-1-(4-morpholin-4-ylmethyl-phenyl)-5,5-dioxo-4,5-di…Treatment of uveal melanoma | iOnctura SA | Designated |
| Apr 27, 2022 | DarovasertibTreatment of Uveal Melanoma | IDEAYA Biosciences Inc. | Designated |
| Feb 15, 2022 | SalinomycinTreatment of uveal melanoma | Hillstream Biopharma, Inc. | Designated |
| Feb 19, 2021 | 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-t…Treatment of uveal melanoma | Linnaeus Therapeutics, Inc. | Designated |
| Feb 28, 2019 | Ac-225-4-PHenylbutyryl-His-D-Phe-Arg-Trp-Gly-Lys(eAhx-DOTA)-…Treatment of Uveal Melanoma | Modulation Therapeutics Incorporated | Designated |
| Apr 8, 2015 | Modified human papillomavirus capsid protein conjugated to…Treatment of uveal melanoma | Aura Biosciences, Inc. | Designated |
| Jun 24, 2008 | Vincristine sulfate liposomesTreatment of metastatic uveal melanoma. | Acrotech Biopharma LLC | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 1, 2022 | KimmtrakTebentafusp · orphan | Immunocore Ireland Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA